References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J
Clin. 2020;70(1). doi: 10.3322/caac.21590. PubMed PMID: 31912902.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2018;68(6):394-424. doi: 10.3322/caac.21492. PubMed PMID: 30207593.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer
statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32. doi:
10.3322/caac.21338. PubMed PMID: 26808342.
4. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor
receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-81.
PubMed PMID: 17318210.
5. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T.
Mutations of the epidermal growth factor receptor gene in lung cancer:
biological and clinical implications. Cancer Res. 2004;64(24):8919-23.
PubMed PMID: 15604253.
6. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor
antagonists in the biology and treatment of cancer. J Clin Oncol.
2003;21(14):2787-99. PubMed PMID: 12860957.
7. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor
mutations in non-small-cell lung cancer: implications for treatment and
tumor biology. J Clin Oncol. 2005;23(14):3227-34. PubMed PMID: 15886310.
8. Han S-W, Kim T-Y, Hwang PG, Jeong S, Kim J, Choi IS, et al.
Predictive and prognostic impact of epidermal growth factor receptor
mutation in non-small-cell lung cancer patients treated with gefitinib.
J Clin Oncol. 2005;23(11):2493-501. PubMed PMID: 15710947.
9. Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, et
al. A prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154-62.
doi: 10.1097/JTO.0000000000000033. PubMed PMID: 24419411.
10. Engelman JA, Jänne PA. Factors predicting response to EGFR tyrosine
kinase inhibitors. Semin Respir Crit Care Med. 2005;26(3):314-22. PubMed
PMID: 16052433.
11. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl
J Med. 2009;361(10):947-57. doi: 10.1056/NEJMoa0810699. PubMed PMID:
19692680.
12. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et
al. Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 2010;362(25):2380-8. doi:
10.1056/NEJMoa0909530. PubMed PMID: 20573926.
13. Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, et
al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients
with advanced non-small-cell lung cancer (INVITE): a randomized, phase
II study. J Clin Oncol. 2008;26(26):4253-60. doi:
10.1200/JCO.2007.15.0672. PubMed PMID: 18779612.
14. Sun J-M, Lee KH, Kim S-W, Lee DH, Min YJ, Yun HJ, et al. Gefitinib
versus pemetrexed as second-line treatment in patients with nonsmall
cell lung cancer previously treated with platinum-based chemotherapy
(KCSG-LU08-01): an open-label, phase 3 trial. Cancer.
2012;118(24):6234-42. doi: 10.1002/cncr.27630. PubMed PMID: 22674612.
15. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J,
et al. Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal growth
factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Lancet Oncol. 2010;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X.
PubMed PMID: 20022809.
16. Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line
erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR
mutation-positive non-small-cell lung cancer: analyses from the phase
III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883-9.
doi: 10.1093/annonc/mdv270. PubMed PMID: 26105600.
17. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall
survival results from a randomised, phase III study of erlotinib versus
chemotherapy as first-line treatment of EGFR mutation-positive advanced
non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol.
2015;26(9):1877-83. doi: 10.1093/annonc/mdv276. PubMed PMID: 26141208.
18. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib
versus chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802):
a multicentre, open-label, randomised, phase 3 study. Lancet Oncol.
2011;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. PubMed PMID:
21783417.
19. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S,
Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated
patients with advanced non-small cell lung cancer: a Hellenic Oncology
Research Group (HORG) randomized phase 3 study. Cancer.
2013;119(15):2754-64. doi: 10.1002/cncr.28132. PubMed PMID: 23661337.
20. Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, et al. Erlotinib as
second-line treatment in patients with advanced non-small-cell lung
cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
Ann Oncol. 2013;24(4):993-9. doi: 10.1093/annonc/mds529. PubMed PMID:
23129122.
21. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E,
et al. Erlotinib versus standard chemotherapy as first-line treatment
for European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46. doi:
10.1016/S1470-2045(11)70393-X. PubMed PMID: 22285168.
22. Schuler M, Wu Y-L, Hirsh V, O’Byrne K, Yamamoto N, Mok T, et al.
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell
Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations
and Brain Metastases. J Thorac Oncol. 2016;11(3):380-90. doi:
10.1016/j.jtho.2015.11.014. PubMed PMID: 26823294.
23. Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, et al. Afatinib
versus cisplatin plus gemcitabine for first-line treatment of Asian
patients with advanced non-small-cell lung cancer harbouring EGFR
mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet
Oncol. 2014;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. PubMed
PMID: 24439929.
24. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al.
Phase III study of afatinib or cisplatin plus pemetrexed in patients
with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol.
2013;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. PubMed PMID:
23816960.
25. Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, et al.
Afatinib versus cisplatin plus pemetrexed in Japanese patients with
advanced non-small cell lung cancer harboring activating EGFR mutations:
Subgroup analysis of LUX-Lung 3. Cancer Sci. 2015;106(9):1202-11. doi:
10.1111/cas.12723. PubMed PMID: 26094656.
26. Wu Y-L, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al.
Dacomitinib versus gefitinib as first-line treatment for patients with
EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a
randomised, open-label, phase 3 trial. Lancet Oncol.
2017;18(11):1454-66. doi: 10.1016/S1470-2045(17)30608-3. PubMed PMID:
28958502.
27. Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al.
Improvement in Overall Survival in a Randomized Study That Compared
Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung
Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018;36(22):2244-50.
doi: 10.1200/JCO.2018.78.7994. PubMed PMID: 29864379.
28. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong
B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced
Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-25. doi:
10.1056/NEJMoa1713137. PubMed PMID: 29151359.
29. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y,
et al. Overall Survival with Osimertinib in Untreated, -Mutated Advanced
NSCLC. N Engl J Med. 2020;382(1):41-50. doi: 10.1056/NEJMoa1913662.
PubMed PMID: 31751012.
30. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N
Engl J Med. 2017;376(7):629-40. doi: 10.1056/NEJMoa1612674. PubMed PMID:
27959700.
31. Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, et al.
Osimertinib in Japanese patients with EGFR T790M mutation-positive
advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci.
2018;109(6):1930-8. doi: 10.1111/cas.13623. PubMed PMID: 29697876.
32. Wu Y-L, Ahn M-J, Garassino MC, Han J-Y, Katakami N, Kim HR, et al.
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced
Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial
(AURA3). J Clin Oncol. 2018;36(26):2702-9. doi:
10.1200/JCO.2018.77.9363. PubMed PMID: 30059262.
33. Nie K, Zhang Z, Zhang C, Geng C, Zhang L, Xu X, et al. Osimertinib
compared docetaxel-bevacizumab as third-line treatment in EGFR T790M
mutated non-small-cell lung cancer. Lung Cancer. 2018;121. doi:
10.1016/j.lungcan.2018.04.012. PubMed PMID: 29858027.
34. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al.
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is
associated with a second mutation in the EGFR kinase domain. PLoS Med.
2005;2(3):e73. PubMed PMID: 15737014.
35. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB,
Fidias P, et al. Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR inhibitors. Sci Transl Med.
2011;3(75):75ra26. doi: 10.1126/scitranslmed.3002003. PubMed PMID:
21430269.
36. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al.
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin
Cancer Res. 2013;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246.
PubMed PMID: 23470965.
37. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et
al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in
non-small cell lung cancer harboring EGFR T790M. Nat Med.
2015;21(6):560-2. doi: 10.1038/nm.3854. PubMed PMID: 25939061.
38. Jia Y, Yun C-H, Park E, Ercan D, Manuia M, Juarez J, et al.
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective
allosteric inhibitors. Nature. 2016;534(7605):129-32. doi:
10.1038/nature17960. PubMed PMID: 27251290.
39. Zhang Q, Zhang X-C, Yang J-J, Yang Z-F, Bai Y, Su J, et al. EGFR
L792H and G796R: Two Novel Mutations Mediating Resistance to the
Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib. J Thorac
Oncol. 2018;13(9):1415-21. doi: 10.1016/j.jtho.2018.05.024. PubMed PMID:
29857056.
40. Hanahan D, Coussens LM. Accessories to the crime: functions of cells
recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309-22.
doi: 10.1016/j.ccr.2012.02.022. PubMed PMID: 22439926.
41. Quail DF, Joyce JA. Microenvironmental regulation of tumor
progression and metastasis. Nat Med. 2013;19(11):1423-37. doi:
10.1038/nm.3394. PubMed PMID: 24202395.
42. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a
glance. J Cell Sci. 2010;123(Pt 24):4195-200. doi: 10.1242/jcs.023820.
PubMed PMID: 21123617.
43. Lo H-W, Hsu S-C, Xia W, Cao X, Shih J-Y, Wei Y, et al. Epidermal
growth factor receptor cooperates with signal transducer and activator
of transcription 3 to induce epithelial-mesenchymal transition in cancer
cells via up-regulation of TWIST gene expression. Cancer Res.
2007;67(19):9066-76. PubMed PMID: 17909010.
44. Hugo HJ, Wafai R, Blick T, Thompson EW, Newgreen DF. Staurosporine
augments EGF-mediated EMT in PMC42-LA cells through actin
depolymerisation, focal contact size reduction and Snail1 induction - a
model for cross-modulation. BMC Cancer. 2009;9:235. doi:
10.1186/1471-2407-9-235. PubMed PMID: 19604397.
45. Zuo J-H, Zhu W, Li M-Y, Li X-H, Yi H, Zeng G-Q, et al. Activation of
EGFR promotes squamous carcinoma SCC10A cell migration and invasion via
inducing EMT-like phenotype change and MMP-9-mediated degradation of
E-cadherin. J Cell Biochem. 2011;112(9):2508-17. doi: 10.1002/jcb.23175.
PubMed PMID: 21557297.
46. Zuo J, Wen M, Li S, Lv X, Wang L, Ai X, et al. Overexpression of
CXCR4 promotes invasion and migration of non-small cell lung cancer via
EGFR and MMP-9. Oncol Lett. 2017;14(6):7513-21. doi:
10.3892/ol.2017.7168. PubMed PMID: 29344197.
47. Wang Y, Zhang T, Guo L, Ren T, Yang Y. Stromal extracellular matrix
is a microenvironmental cue promoting resistance to EGFR tyrosine kinase
inhibitors in lung cancer cells. Int J Biochem Cell Biol. 2019;106. doi:
10.1016/j.biocel.2018.11.001. PubMed PMID: 30471423.
48. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer.
2006;6(5):392-401. PubMed PMID: 16572188.
49. Yi Y, Zeng S, Wang Z, Wu M, Ma Y, Ye X, et al. Cancer-associated
fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI
resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
Biochim Biophys Acta Mol Basis Dis. 2018;1864(3):793-803. doi:
10.1016/j.bbadis.2017.12.021. PubMed PMID: 29253515.
50. Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura
Y, et al. CD200-positive cancer associated fibroblasts augment the
sensitivity of Epidermal Growth Factor Receptor mutation-positive lung
adenocarcinomas to EGFR Tyrosine kinase inhibitors. Sci Rep.
2017;7:46662. doi: 10.1038/srep46662. PubMed PMID: 28429795.
51. Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, et al.
Podoplanin-positive cancer-associated fibroblasts in the tumor
microenvironment induce primary resistance to EGFR-TKIs in lung
adenocarcinoma with EGFR mutation. Clin Cancer Res. 2015;21(3):642-51.
doi: 10.1158/1078-0432.CCR-14-0846. PubMed PMID: 25388165.
52. Arena S, Salati M, Sorgentoni G, Barbisan F, Orciani M.
Characterization of tumor-derived mesenchymal stem cells potentially
differentiating into cancer-associated fibroblasts in lung cancer. Clin
Transl Oncol. 2018;20(12):1582-91. doi: 10.1007/s12094-018-1894-4.
PubMed PMID: 29796998.
53. Carmeliet P. Angiogenesis in health and disease. Nat Med.
2003;9(6):653-60. PubMed PMID: 12778163.
54. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role
of the HIF system. Nat Med. 2003;9(6):677-84. PubMed PMID: 12778166.
55. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its
receptors. Nat Med. 2003;9(6):669-76. PubMed PMID: 12778165.
56. Togashi Y, Masago K, Kubo T, Fujimoto D, Sakamori Y, Nagai H, et al.
Association between vascular-poor area of primary tumors and epidermal
growth factor receptor gene status in advanced lung adenocarcinoma. Med
Oncol. 2012;29(5):3169-75. doi: 10.1007/s12032-012-0235-7. PubMed PMID:
22492281.
57. Yuan X-H, Yang J, Wang X-Y, Zhang X-L, Qin T-T, Li K. Association
between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in
lung adenocarcinoma. Oncol Lett. 2018;16(2):2105-12. doi:
10.3892/ol.2018.8901. PubMed PMID: 30008907.
58. Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, et
al. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in
EGFR-mutant lung cancer by decreasing client protein expression and
angiogenesis. J Thorac Oncol. 2012;7(7):1078-85. doi:
10.1097/JTO.0b013e3182519a2c. PubMed PMID: 22592212.
59. Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, et
al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of
HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR
mutation. J Thorac Oncol. 2014;9(6):775-83. doi:
10.1097/JTO.0000000000000170. PubMed PMID: 24828661.
60. Lee JG, Wu R. Erlotinib-cisplatin combination inhibits growth and
angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in
vitro and in vivo. Neoplasia. 2015;17(2):190-200. doi:
10.1016/j.neo.2014.12.008. PubMed PMID: 25748238.
61. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related
inflammation. Nature. 2008;454(7203):436-44. doi: 10.1038/nature07205.
PubMed PMID: 18650914.
62. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili
S-A, Mardani F, et al. Macrophage plasticity, polarization, and function
in health and disease. J Cell Physiol. 2018;233(9):6425-40. doi:
10.1002/jcp.26429. PubMed PMID: 29319160.
63. Li Z, Maeda D, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K, et al.
The intratumoral distribution influences the prognostic impact of CD68-
and CD204-positive macrophages in non-small cell lung cancer. Lung
Cancer. 2018;123:127-35. doi: 10.1016/j.lungcan.2018.07.015. PubMed
PMID: 30089583.
64. Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S,
et al. Aggressive tumor microenvironment of solid predominant lung
adenocarcinoma subtype harboring with epidermal growth factor receptor
mutations. Lung Cancer. 2016;91. doi: 10.1016/j.lungcan.2015.11.012.
PubMed PMID: 26711928.
65. Feng P-H, Yu C-T, Chen K-Y, Luo C-S, Wu SM, Liu C-Y, et al. S100A9
MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the
role of RELB. Oncotarget. 2018;9(7):7631-43. doi:
10.18632/oncotarget.24146. PubMed PMID: 29484139.
66. Qian B-Z, Pollard JW. Macrophage diversity enhances tumor
progression and metastasis. Cell. 2010;141(1):39-51. doi:
10.1016/j.cell.2010.03.014. PubMed PMID: 20371344.
67. Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou W, et al. M2-polarized
macrophages contribute to the decreased sensitivity of EGFR-TKIs
treatment in patients with advanced lung adenocarcinoma. Med Oncol.
2014;31(8):127. doi: 10.1007/s12032-014-0127-0. PubMed PMID: 25034365.
68. Waisman A, Lukas D, Clausen BE, Yogev N. Dendritic cells as
gatekeepers of tolerance. Semin Immunopathol. 2017;39(2):153-63. doi:
10.1007/s00281-016-0583-z. PubMed PMID: 27456849.
69. Venugopalan A, Lee M-J, Niu G, Medina-Echeverz J, Tomita Y, Lizak
MJ, et al. EGFR-targeted therapy results in dramatic early lung tumor
regression accompanied by imaging response and immune infiltration in
EGFR mutant transgenic mouse models. Oncotarget. 2016;7(34):54137-56.
doi: 10.18632/oncotarget.11021. PubMed PMID: 27494838.
70. Yu S, Sha H, Qin X, Chen Y, Li X, Shi M, et al. EGFR E746-A750
deletion in lung cancer represses antitumor immunity through the
exosome-mediated inhibition of dendritic cells. Oncogene.
2020;39(13):2643-57. doi: 10.1038/s41388-020-1182-y. PubMed PMID:
32001818.
71. Nigro A, Ricciardi L, Salvato I, Sabbatino F, Vitale M, Crescenzi
MA, et al. Enhanced Expression of CD47 Is Associated With Off-Target
Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC. Front
Immunol. 2019;10:3135. doi: 10.3389/fimmu.2019.03135. PubMed PMID:
32082304.
72. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance.
Oncogene. 2008;27(45):5932-43. doi: 10.1038/onc.2008.267. PubMed PMID:
18836474.
73. Tu C, Zhu Y, Jiang B, He W, Jin C. Correlation between circulating
tumor cells EGFR expression and T cell subsets in advanced non-small
cell lung cancer patients after tyrosine kinase inhibitor treatment.
Neoplasma. 2017;64(4):619-25. doi: 10.4149/neo_2017_418. PubMed PMID:
28485170.
74. Park H-R, Ahn Y-O, Kim TM, Kim S, Kim S, Lee YS, et al. NK92-CD16
cells are cytotoxic to non-small cell lung cancer cell lines that have
acquired resistance to tyrosine kinase inhibitors. Cytotherapy.
2019;21(6):603-11. doi: 10.1016/j.jcyt.2019.03.312. PubMed PMID:
31010733.
75. He S, Yin T, Li D, Gao X, Wan Y, Ma X, et al. Enhanced interaction
between natural killer cells and lung cancer cells: involvement in
gefitinib-mediated immunoregulation. J Transl Med. 2013;11:186. doi:
10.1186/1479-5876-11-186. PubMed PMID: 23937717.
76. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends
Immunol. 2016;37(3):208-20. doi: 10.1016/j.it.2016.01.004. PubMed PMID:
26858199.
77. Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol
Res. 2017;5(1):3-8. doi: 10.1158/2326-6066.CIR-16-0297. PubMed PMID:
28052991.
78. Feng P-H, Chen K-Y, Huang Y-C, Luo C-S, Wu SM, Chen T-T, et al.
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control
in Patients with EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol.
2018;13(7):958-67. doi: 10.1016/j.jtho.2018.03.032. PubMed PMID:
29684573.
79. Liew PX, Kubes P. The Neutrophil’s Role During Health and Disease.
Physiol Rev. 2019;99(2):1223-48. doi: 10.1152/physrev.00012.2018. PubMed
PMID: 30758246.
80. Zhang Y, Feng Y-C, Zhu H-G, Xiong T-C, Hou Y-S, Song J, et al. The
peripheral blood neutrophil-to-lymphocyte ratio is a prognostic
predictor for survival of EGFR-mutant nonsmall cell lung cancer patients
treated with EGFR-TKIs. Medicine (Baltimore). 2018;97(30):e11648. doi:
10.1097/MD.0000000000011648. PubMed PMID: 30045314.
81. Meriggi F, Codignola C, Beretta GD, Ceresoli GL, Caprioli A,
Scartozzi M, et al. Significance of neutrophil-to-lymphocyte ratio in
Western advanced EGFR-mutated non-small cell lung cancer receiving a
targeted therapy. Tumori. 2017;103(5):443-8. doi: 10.5301/tj.5000632.
PubMed PMID: 28731495.
82. Lin G-N, Peng J-W, Liu P-P, Liu D-Y, Xiao J-J, Chen X-Q. Elevated
neutrophil-to-lymphocyte ratio predicts poor outcome in patients with
advanced non-small-cell lung cancer receiving first-line gefitinib or
erlotinib treatment. Asia Pac J Clin Oncol. 2017;13(5):e189-e94. doi:
10.1111/ajco.12273. PubMed PMID: 25359280.
83. Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, et
al. Intratumoral Immune Cell Densities Are Associated with Lung
Adenocarcinoma Gene Alterations. Am J Respir Crit Care Med.
2016;194(11):1403-12. PubMed PMID: 27299180.
84. Franchina DG, Grusdat M, Brenner D. B-Cell Metabolic Remodeling and
Cancer. Trends Cancer. 2018;4(2):138-50. doi:
10.1016/j.trecan.2017.12.006. PubMed PMID: 29458963.
85. Wang C, Yin R, Dai J, Gu Y, Cui S, Ma H, et al. Whole-genome
sequencing reveals genomic signatures associated with the inflammatory
microenvironments in Chinese NSCLC patients. Nat Commun. 2018;9(1):2054.
doi: 10.1038/s41467-018-04492-2. PubMed PMID: 29799009.
86. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et
al. Presence of B cells in tertiary lymphoid structures is associated
with a protective immunity in patients with lung cancer. Am J Respir
Crit Care Med. 2014;189(7):832-44. doi: 10.1164/rccm.201309-1611OC.
PubMed PMID: 24484236.
87. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, et al.
The prognostic relevance of tumour-infiltrating plasma cells and
immunoglobulin kappa C indicates an important role of the humoral immune
response in non-small cell lung cancer. Cancer Lett. 2013;333(2):222-8.
doi: 10.1016/j.canlet.2013.01.036. PubMed PMID: 23370224.
88. Bruno TC, Ebner PJ, Moore BL, Squalls OG, Waugh KA, Eruslanov EB, et
al. Antigen-Presenting Intratumoral B Cells Affect CD4 TIL Phenotypes in
Non-Small Cell Lung Cancer Patients. Cancer Immunol Res.
2017;5(10):898-907. doi: 10.1158/2326-6066.CIR-17-0075. PubMed PMID:
28848053.
89. Cai X, Zhang L, Wei W. Regulatory B cells in inflammatory diseases
and tumor. Int Immunopharmacol. 2019;67:281-6. doi:
10.1016/j.intimp.2018.12.007. PubMed PMID: 30572252.
90. Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in
anti-tumor immunity. Int Immunol. 2015;27(10):521-30. doi:
10.1093/intimm/dxv034. PubMed PMID: 25999597.
91. Kumar BV, Connors TJ, Farber DL. Human T Cell Development,
Localization, and Function throughout Life. Immunity. 2018;48(2):202-13.
doi: 10.1016/j.immuni.2018.01.007. PubMed PMID: 29466753.
92. Zhang X-C, Wang J, Shao G-G, Wang Q, Qu X, Wang B, et al.
Comprehensive genomic and immunological characterization of Chinese
non-small cell lung cancer patients. Nat Commun. 2019;10(1):1772. doi:
10.1038/s41467-019-09762-1. PubMed PMID: 30992440.
93. Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW, et al.
Bystander CD8 T cells are abundant and phenotypically distinct in human
tumour infiltrates. Nature. 2018;557(7706):575-9. doi:
10.1038/s41586-018-0130-2. PubMed PMID: 29769722.
94. Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau
J, et al. TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile
and the Response to Anti-PD-1 in Lung Adenocarcinoma. Clin Cancer Res.
2018;24(22):5710-23. Epub 2018/05/17. doi:
10.1158/1078-0432.CCR-18-0163. PubMed PMID: 29764856.
95. Dong Z-Y, Zhang J-T, Liu S-Y, Su J, Zhang C, Xie Z, et al. EGFR
mutation correlates with uninflamed phenotype and weak immunogenicity,
causing impaired response to PD-1 blockade in non-small cell lung
cancer. Oncoimmunology. 2017;6(11):e1356145. doi:
10.1080/2162402X.2017.1356145. PubMed PMID: 29147605.
96. Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F,
et al. Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating
Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in
NSCLC with a Prognostic and Predictive Value. Clin Cancer Res.
2018;24(2):407-19. doi: 10.1158/1078-0432.CCR-17-2156. PubMed PMID:
29074606.
97. Busch SE, Hanke ML, Kargl J, Metz HE, MacPherson D, Houghton AM.
Lung Cancer Subtypes Generate Unique Immune Responses. J Immunol.
2016;197(11):4493-503. PubMed PMID: 27799309.
98. Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, et al.
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human
Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric
Single-Cell Analysis. Clin Cancer Res. 2019;25(15):4663-73. doi:
10.1158/1078-0432.CCR-18-4142. PubMed PMID: 31053602.
99. Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation
of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven
NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC
Patients with EGFR Mutation. J Thorac Oncol. 2015;10(6):910-23. doi:
10.1097/JTO.0000000000000500. PubMed PMID: 25658629.
100. Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, et
al. Blockade of EGFR improves responsiveness to PD-1 blockade in
-mutated non-small cell lung cancer. Sci Immunol. 2020;5(43). doi:
10.1126/sciimmunol.aav3937. PubMed PMID: 32005679.
101. Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K,
et al. Mutational activation of the epidermal growth factor receptor
down-regulates major histocompatibility complex class I expression via
the extracellular signal-regulated kinase in non-small cell lung cancer.
Cancer Sci. 2019;110(1):52-60. doi: 10.1111/cas.13860. PubMed PMID:
30390416.
102. Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M.
Prognostic value of Cox-2 and PD-L1 expression and its relationship with
tumor-infiltrating lymphocytes in resected lung adenocarcinoma. Cancer
Manag Res. 2017;9:741-50. doi: 10.2147/CMAR.S146897. PubMed PMID:
29238224.
103. Liu S-Y, Dong Z-Y, Wu S-P, Xie Z, Yan L-X, Li Y-F, et al. Clinical
relevance of PD-L1 expression and CD8+ T cells infiltration in patients
with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer.
2018;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. PubMed PMID:
30429043.
104. Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, et
al. Tumor immune microenvironment and nivolumab efficacy in EGFR
mutation-positive non-small-cell lung cancer based on T790M status after
disease progression during EGFR-TKI treatment. Ann Oncol.
2017;28(7):1532-9. doi: 10.1093/annonc/mdx183. PubMed PMID: 28407039.
105. Meniawy TM, Lake RA, McDonnell AM, Millward MJ, Nowak AK. PD-L1 on
peripheral blood T lymphocytes is prognostic in patients with non-small
cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer.
2016;93. doi: 10.1016/j.lungcan.2015.12.006. PubMed PMID: 26898608.
106. Chen K, Cheng G, Zhang F, Zhu G, Xu Y, Yu X, et al. PD-L1
expression and T cells infiltration in patients with uncommon
EGFR-mutant non-small cell lung cancer and the response to
immunotherapy. Lung Cancer. 2020;142. doi:
10.1016/j.lungcan.2020.02.010. PubMed PMID: 32120230.
107. Waldmann TA. Cytokines in Cancer Immunotherapy. Cold Spring Harb
Perspect Biol. 2018;10(12). doi: 10.1101/cshperspect.a028472. PubMed
PMID: 29101107.
108. Wang D-H, Lee H-S, Yoon D, Berry G, Wheeler TM, Sugarbaker DJ, et
al. Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar
Macrophages. Clin Cancer Res. 2017;23(3):778-88. doi:
10.1158/1078-0432.CCR-15-2597. PubMed PMID: 27496865.
109. Jiang X-M, Xu Y-L, Huang M-Y, Zhang L-L, Su M-X, Chen X, et al.
Osimertinib (AZD9291) decreases programmed death ligand-1 in
EGFR-mutated non-small cell lung cancer cells. Acta Pharmacol Sin.
2017;38(11):1512-20. doi: 10.1038/aps.2017.123. PubMed PMID: 28880013.
110. Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H, et al. Amphiregulin
Confers Regulatory T Cell Suppressive Function and Tumor Invasion via
the EGFR/GSK-3β/Foxp3 Axis. J Biol Chem. 2016;291(40):21085-95. PubMed
PMID: 27432879.
111. Tsukita Y, Fujino N, Miyauchi E, Saito R, Fujishima F, Itakura K,
et al. Axl kinase drives immune checkpoint and chemokine signalling
pathways in lung adenocarcinomas. Mol Cancer. 2019;18(1):24. doi:
10.1186/s12943-019-0953-y. PubMed PMID: 30744655.
112. Joseph NA, Chiou S-H, Lung Z, Yang C-L, Lin T-Y, Chang H-W, et al.
The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR
resistance and epithelial-to-mesenchymal transition of lung
adenocarcinoma cells. J Hematol Oncol. 2018;11(1):74. doi:
10.1186/s13045-018-0557-9. PubMed PMID: 29855336.
113. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, et
al. Hepatocyte growth factor expression in EGFR mutant lung cancer with
intrinsic and acquired resistance to tyrosine kinase inhibitors in a
Japanese cohort. J Thorac Oncol. 2011;6(12):2011-7. doi:
10.1097/JTO.0b013e31823ab0dd. PubMed PMID: 22052230.
114. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, et
al. Hepatocyte growth factor induces resistance to anti-epidermal growth
factor receptor antibody in lung cancer. J Thorac Oncol.
2012;7(2):272-80. doi: 10.1097/JTO.0b013e3182398e69. PubMed PMID:
22089117.
115. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, et al.
Hepatocyte growth factor reduces susceptibility to an irreversible
epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung
cancer. Clin Cancer Res. 2010;16(1):174-83. doi:
10.1158/1078-0432.CCR-09-1204. PubMed PMID: 20008840.
116. Han J-Y, Kim JY, Lee SH, Yoo NJ, Choi BG. Association between
plasma hepatocyte growth factor and gefitinib resistance in patients
with advanced non-small cell lung cancer. Lung Cancer. 2011;74(2):293-9.
doi: 10.1016/j.lungcan.2011.02.021. PubMed PMID: 21440951.
117. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al.
Hepatocyte growth factor induces gefitinib resistance of lung
adenocarcinoma with epidermal growth factor receptor-activating
mutations. Cancer Res. 2008;68(22):9479-87. doi:
10.1158/0008-5472.CAN-08-1643. PubMed PMID: 19010923.
118. Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions
involved in resistance formation to tyrosine kinase inhibitors.
Oncogene. 2013;32(33):3846-56. doi: 10.1038/onc.2012.396. PubMed PMID:
23045285.
119. Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, et
al. Reaction of plasma hepatocyte growth factor levels in non-small cell
lung cancer patients treated with EGFR-TKIs. Int J Cancer.
2011;129(6):1410-6. doi: 10.1002/ijc.25799. PubMed PMID: 21128242.
120. Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, et al.
Impact of serum hepatocyte growth factor on treatment response to
epidermal growth factor receptor tyrosine kinase inhibitors in patients
with non-small cell lung adenocarcinoma. Clin Cancer Res.
2010;16(18):4616-24. doi: 10.1158/1078-0432.CCR-10-0383. PubMed PMID:
20679350.
121. Jiao D, Chen J, Li Y, Tang X, Wang J, Xu W, et al. miR-1-3p and
miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer
cells through inhibition of c-Met signalling and EMT. J Cell Mol Med.
2018;22(7):3526-36. doi: 10.1111/jcmm.13629. PubMed PMID: 29664235.
122. Zhang Y, Zeng Y, Liu T, Du W, Zhu J, Liu Z, et al. The canonical
TGF-β/Smad signalling pathway is involved in PD-L1-induced primary
resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Respir Res. 2019;20(1):164. doi: 10.1186/s12931-019-1137-4. PubMed PMID:
31331328.
123. Zhang L, Li QX, Wu HL, Lu X, Yang M, Yu SY, et al. SNPs in the
transforming growth factor-β pathway as predictors of outcome in
advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Ann Oncol. 2014;25(8):1584-90. doi: 10.1093/annonc/mdu172. PubMed PMID:
24928833.
124. Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker
JH, et al. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in
Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase
Inhibition. Cancer Res. 2015;75(20):4372-83. doi:
10.1158/0008-5472.CAN-15-0377. PubMed PMID: 26282169.
125. Zhu Q, Zhang Z, Lu C, Xu F, Mao W, Zhang K, et al. Gefitinib
promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1
signaling pathway in lung cancer cells harboring EGFR mutation. Clin
Transl Oncol. 2020. doi: 10.1007/s12094-019-02266-w. PubMed PMID:
31900845.
126. Abera MB, Kazanietz MG. Protein kinase Cα mediates erlotinib
resistance in lung cancer cells. Mol Pharmacol. 2015;87(5):832-41. doi:
10.1124/mol.115.097725. PubMed PMID: 25724832.
127. Shen H, Guan D, Shen J, Wang M, Chen X, Xu T, et al. TGF-β1 induces
erlotinib resistance in non-small cell lung cancer by down-regulating
PTEN. Biomed Pharmacother. 2016;77:1-6. doi:
10.1016/j.biopha.2015.10.018. PubMed PMID: 26796257.
128. Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, et
al. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase
switch that induces resistance to EGFR inhibitors. Cancer Res.
2014;74(14):3995-4005. doi: 10.1158/0008-5472.CAN-14-0110. PubMed PMID:
24830724.
129. Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, et
al. Potential influence of interleukin-6 on the therapeutic effect of
gefitinib in patients with advanced non-small cell lung cancer
harbouring EGFR mutations. Biochem Biophys Res Commun.
2018;495(1):360-7. doi: 10.1016/j.bbrc.2017.10.175. PubMed PMID:
29101033.
130. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, et al. Stress
hormones promote EGFR inhibitor resistance in NSCLC: Implications for
combinations with β-blockers. Sci Transl Med. 2017;9(415). doi:
10.1126/scitranslmed.aao4307. PubMed PMID: 29118262.
131. Jia Y, Li X, Zhao C, Jiang T, Zhao S, Zhang L, et al. Impact of
serum vascular endothelial growth factor and interleukin-6 on treatment
response to epidermal growth factor receptor tyrosine kinase inhibitors
in patients with non-small-cell lung cancer. Lung Cancer. 2018;125:22-8.
doi: 10.1016/j.lungcan.2018.08.025. PubMed PMID: 30429024.
132. Umeguchi H, Sueoka-Aragane N, Kobayashi N, Nakamura T, Sato A,
Takeda Y, et al. Usefulness of plasma HGF level for monitoring acquired
resistance to EGFR tyrosine kinase inhibitors in non-small cell lung
cancer. Oncol Rep. 2015;33(1):391-6. doi: 10.3892/or.2014.3560. PubMed
PMID: 25338771.
133. Cho JH, You Y-M, Yeom YI, Lee DC, Kim B-K, Won M, et al. RNF25
promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing
NF-κB-mediated ERK reactivation. Cell Death Dis. 2018;9(6):587. doi:
10.1038/s41419-018-0651-5. PubMed PMID: 29789542.
134. Ge P, Cao L, Chen X, Jing R, Yue W. miR-762 activation confers
acquired resistance to gefitinib in non-small cell lung cancer. BMC
Cancer. 2019;19(1):1203. doi: 10.1186/s12885-019-6416-4. PubMed PMID:
31823748.
135. Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK,
Palena C. IL-8 signaling is involved in resistance of lung carcinoma
cells to erlotinib. Oncotarget. 2016;7(27):42031-44. doi:
10.18632/oncotarget.9662. PubMed PMID: 27248176.
136. Karachaliou N, Cardona AF, Bracht JWP, Aldeguer E, Drozdowskyj A,
Fernandez-Bruno M, et al. Integrin-linked kinase (ILK) and src homology
2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation
positive non-small cell lung cancer (NSCLC). EBioMedicine.
2019;39:207-14. doi: 10.1016/j.ebiom.2018.11.036. PubMed PMID: 30473379.
137. Wang X, Zhang F, Yang X, Xue M, Li X, Gao Y, et al. Secreted
Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine
Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer. Oncol Res.
2019;27(8):871-7. doi: 10.3727/096504018X15426271404407. PubMed PMID:
30832751.
138. Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, et al. Implication
of epithelial-mesenchymal transition in IGF1R-induced resistance to
EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget.
2015;6(42):44332-45. doi: 10.18632/oncotarget.6293. PubMed PMID:
26554308.
139. Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodríguez ML,
et al. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR
Kinase Inhibitors in NSCLC. Cancer Res. 2019;79(17):4439-52. doi:
10.1158/0008-5472.CAN-19-0024. PubMed PMID: 31273063.